Immediate Impact
64 standout
Citing Papers
NF-κB in biology and targeted therapy: new insights and translational implications
2024 Standout
Bispecific and multispecific antibodies in oncology: opportunities and challenges
2024 Standout
Works of K.H. Lee being referenced
A phase II, multicenter, two cohort study of 160 mg osimertinib in EGFR T790M-positive non-small-cell lung cancer patients with brain metastases or leptomeningeal disease who progressed on prior EGFR TKI therapy
2020
Brigatinib vs crizotinib in patients with ALK inhibitor-naive advanced ALK+ NSCLC: Updated results from the phase III ALTA-1L trial
2019
Author Peers
| Author | Last Decade | Papers | Cites | ||||
|---|---|---|---|---|---|---|---|
| K.H. Lee | 199 | 153 | 1 | 58 | 17 | 228 | |
| Roby Thomas | 113 | 145 | 1 | 54 | 20 | 252 | |
| Susan E. Jorge | 199 | 136 | 112 | 22 | 298 | ||
| Catrin Cox | 132 | 132 | 2 | 89 | 12 | 239 | |
| Mengxi Ge | 173 | 138 | 92 | 14 | 266 | ||
| M. Campone | 85 | 127 | 2 | 78 | 21 | 214 | |
| Delan Li | 111 | 127 | 68 | 13 | 183 | ||
| Carlos Arce‐Lara | 98 | 145 | 4 | 122 | 20 | 273 | |
| Jane Qian | 89 | 201 | 125 | 16 | 254 | ||
| J. Carpenter | 72 | 136 | 2 | 80 | 23 | 238 | |
| Damé Idossa | 68 | 95 | 48 | 20 | 229 |
All Works
Loading papers...